Evolocumab in STEMI

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The goal of this clinical trial is to compare the size of myocardial infarct between evolocumab and control groups in patients with ST segment elevation myocardial infarction who undergoing primary percutaneous coronary intervention(PCI). All study participants will undergo a cardiac MRI 4 weeks after primary reperfusion. The evolocumab group will receive 420 mg before PCI via subcutaneous injection.
Epistemonikos ID: b6665b9fd425500fda3bcd6f093d1d424d77aece
First added on: May 15, 2024